From The Independent:
A combination treatment of two immunotherapy drugs may prove an effective new weapon against advanced kidney cancer, results from a trial have shown. Scientists found that 40 percent of patients treated with nivolumab and ipilimumab experienced a significant reduction in the size of their tumours. In a tenth of these patients the cancer appeared to have vanished. There was no detectable sign of disease. The CheckMate -016 study was an early Phase I trial chiefly designed to investigate doses and side effects.
Read the full article.
